ClinicalTrials.gg
CompletedNCT01005355Updated Jun 18, 2014Results posted

Study of IMC-1121B in Patients With Advanced Solid Tumors

A Phase 1 interventional study of IMC-1121B in Advanced Solid Tumors, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This trial is testing the investigational drug IMC-1121B administered to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available. The rationale for performing this trial is to establish the safety profile and the pharmacokinetics of IMC-1121B.

Read the detailed description

This single center, open-label, single-arm, Phase 1 study will enroll approximately 15 to 18 participants. The actual size will vary depending on the dose-limiting toxicities (DLTs) observed and the resultant sizes of the cohorts. Participants will receive IMC-1121B, administered intravenously, once every 2 or 3 weeks for 6 weeks (one cycle). After one cycle of treatment, participants who have an objective response or stable disease may continue to receive IMC-1121B at the same dose and schedule until disease progression or other withdrawal criteria are met. A minimum of three participants will be enrolled in each cohort. Dose escalation in successive cohorts will occur once all participants complete one cycle of therapy.

Participants will be enrolled sequentially into each cohort.

A completed participant will be either a participant who completes the initial 6 week treatment period (Cycle 1) or a participant who discontinues therapy for an IMC-1121B related toxicity during Cycle 1. Participants who do not complete the first 6 weeks of treatment for reasons other than an IMC-1121B -related toxicity will be replaced. Toxicity data for each cohort will be reviewed prior to dose escalation. Upon completion of all required safety evaluations during the initial 6 weeks, the next cohort of new participants will be treated at the next higher dose level using a dose escalation scheme.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Solid tumor
  • recombinant human IgG1
  • MAB
  • monoclonal antibody
  • VEGFR 2
  • human vascular endothelial growth factor receptor 2
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Solid tumor participant who was been histopathologically or documented.
  • Advanced primary or recurrent solid tumors participant who has not responded to standard therapy or no standard therapy is available.
  • The participant has measurable or nonmeasurable lesions according to (RECIST).
  • The participant has an (ECOG) performance status (PS) score of 0-1 at study entry.
  • The participant is able to provide written .
  • The participant is age 20 years or older.
  • The participant has a of > 3 months.
  • The participant has adequate hematologic function, as defined by:
  • An (ANC) > 1500/cubic millimeter (mm³) or /microliter (µL)
  • A level > 10 grams/deciliter (g/dL)
  • A count > 100,000/mm³ or /µL
  • The participant has adequate hepatic function, as defined by:
  • A total level \< 1.8 milligrams/deciliter (mg/dL)
  • (AST) levels \< 86 International Units/liter (IU/L)
  • Alanine transaminase (ALT) levels ≤ 86 IU/L
  • The participant has adequate renal function, as defined by:
  • Serum creatinine level ≤ 1.5 mg/dL, or
  • Calculated serum (Cockcroft-Gault) ≥ 60 milliliters/minute (mL/min)
  • The participant's urinary protein is 0 on dipstick or 1+ but participant does not have edema nor serum albumin \< lower level of normal (LLN).
  • The participant has adequate coagulation function, as defined by (INR) ≤ 1.5.
  • The participant agrees to use adequate during the study period and for 12 weeks after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • The participant has had chemotherapy or therapeutic radiotherapy within 28 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or participant has ongoing side effects ≥ Grade 2 due to agents administered more than 28 days earlier.
  • The participant has obvious evidence of intratumor cavitation.
  • The participant has undergone major surgery (example, laparotomy, thoracotomy, removal of organ[s]) within 28 days prior to study entry, or subcutaneous venous access device placement within 7 days prior to study entry.
  • The participant has a history of postoperative bleeding complications or wound complications from a surgical procedure.
  • The participant has elective or planned surgery to be conducted during the trial.
  • The participant has documented and/or symptomatic brain or . (Participants who are clinically stable [no symptoms during 4 weeks prior to the enrollment] with an assessment that no further treatment [radiation, surgical excision, and administration of ] is required, are permitted to enter the study.)
  • The participant has uncontrolled intercurrent illness including, but not limited to:
  • Thrombotic or hemorrhagic disorders
  • Hemoptysis (approximately one-half of a teaspoon)
  • Ongoing or active infection requiring systemic antibiotic treatment
  • Congestive heart failure (Class III or IV of the classification for heart disease)
  • Angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
  • Uncontrolled hypertension (systolic blood pressure > 150 millimeters of mercury (mmHg), diastolic blood pressure > 95 mm Hg)
  • Cardiac arrhythmia requires treatment [National Cancer Institute , Version 3.0 (NCI-CTCAE v 3.0), Grade 3], or asymptomatic sustained ventricular tachycardia)
  • Peripheral neuropathy of any etiology ≥ Grade 2 (NCI-CTCAE v 3.0)
  • The participant has participated in clinical studies of non-approved experimental agents or procedures within 4 weeks prior to study entry for small molecules, or 8 weeks prior to study entry for non-approved monoclonal antibodies.
  • The participant, if female, is pregnant (confirmed by urine or serum pregnancy test) or lactating.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    IMC-1121B

    Participants receiving IMC-1121B intravenously

    Biological: IMC-1121B

Interventions

  • BiologicalIMC-1121B

    Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.

    Also known as: RAMUCIRUMAB, LY3009806

06

What researchers measure

Primary outcomes

  1. Number of Participants With Drug-Related Adverse Events

    Data presented are the number of participants who experienced adverse events (AE) of any grade, AE of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), serious adverse events (SAE) and AE resulting in death that was considered to be related to IMC-1121B (ramucirumab). A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.

    Time frame: Baseline to study completion up to 48 weeks

  2. IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 1 and 2

    Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle

  3. IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  4. IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) Versus Time Curve - Cohorts 1 and 2 During Cycles 1 and 2

    AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).

    Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle

  5. IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohorts 1 and 2 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  6. IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohorts 1 and 2 During Cycles 1 and 2

    Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle

  7. IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohorts 1 and 2 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  8. IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 1 and 2

    Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle

  9. IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  10. IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 1 and 2

    Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle

  11. IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  12. IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohort 3 During Cycles 1 and 2

    AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).

    Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle

  13. IMC-1121B Pharmacokinetics - Area Under the Concentration (AUC) - Cohort 3 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  14. IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohort 3 During Cycles 1 and 2

    Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle

  15. IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohort 3 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

  16. IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 1 and 2

    Time frame: Day 1 and Day 22 of Cycles 1 and 2 of a 6-week cycle

  17. IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 3 to 5

    Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.

    Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour post-dose

Secondary outcomes

  1. Screen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity)

    Data presented are the number of participants with treatment emergent antibody positive.

    Time frame: Baseline to study completion up to 48 weeks

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)
Started366
Received at least 1 dose of study drug366
Completed366
Not completed000

Outcome measures

PrimaryNumber of Participants With Drug-Related Adverse Events

Data presented are the number of participants who experienced adverse events (AE) of any grade, AE of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), serious adverse events (SAE) and AE resulting in death that was considered to be related to IMC-1121B (ramucirumab). A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.

Time frame:
Baseline to study completion up to 48 weeks
Reported as:
Number · participants
Number of Participants With Drug-Related Adverse Events
participantsIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)
AE of any grade366
AE of Grade ≥3001
SAE001
AE resulting in death000
PrimaryIMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame:
Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · micrograms/milliliter (mcg/mL)
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 1 and 2
micrograms/milliliter (mcg/mL)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)
Cycle 1284 ± 63.7371 ± 113
Cycle 2 (n=1, 2)352 ± NA694 ± 123
PrimaryIMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) Versus Time Curve - Cohorts 1 and 2 During Cycles 1 and 2

AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).

Time frame:
Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · micrograms*hour/milliliter (mcg*h/mL)
IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) Versus Time Curve - Cohorts 1 and 2 During Cycles 1 and 2
micrograms*hour/milliliter (mcg*h/mL)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)
Cycle 1 - AUC(0-∞) (n=1, 1)36900 ± NA73800 ± NA
Cycle 2 - AUCτ (n=1, 2)56400 ± NA102000 ± 10400
PrimaryIMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohorts 1 and 2 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame:
Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Median · hours
IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohorts 1 and 2 During Cycles 1 and 2
hoursIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)
Cycle 1158 ± NA165 ± NA
Cycle 2 (n=0, 0)NA ± NANA ± NA
PrimaryIMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohorts 1 and 2 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame:
Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · milliliters/kilogram (mL/kg)
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 1 and 2
milliliters/kilogram (mL/kg)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)
Cycle 125.0 ± NA21.4 ± NA
Cycle 2 (n=0, 0)NA ± NANA ± NA
PrimaryIMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 1 and 2
Time frame:
Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · micrograms/milliliter (mcg/mL)
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 1 and 2
micrograms/milliliter (mcg/mL)IMC-1121B 10 mg/kg (Cohort 3)
Cycle 1493 ± 122
Cycle 2 (n=2)793 ± 367
PrimaryIMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohort 3 During Cycles 1 and 2

AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).

Time frame:
Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · micrograms*hour/milliliter (mcg*h/mL)
IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohort 3 During Cycles 1 and 2
micrograms*hour/milliliter (mcg*h/mL)IMC-1121B 10 mg/kg (Cohort 3)
Cycle 1 - AUC(0-∞)61600 ± 17100
Cycle 2 - AUCτ103000 ± 26200
PrimaryIMC-1121B Pharmacokinetics - Area Under the Concentration (AUC) - Cohort 3 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohort 3 During Cycles 1 and 2
Time frame:
Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Median · hours
IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohort 3 During Cycles 1 and 2
hoursIMC-1121B 10 mg/kg (Cohort 3)
Cycle 1234 ± NA
Cycle 2 (n=1)329 ± NA
PrimaryIMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohort 3 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose

No measurements were reported for this outcome.

PrimaryIMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 1 and 2
Time frame:
Day 1 and Day 22 of Cycles 1 and 2 of a 6-week cycle
Reported as:
Mean · milliliters/kilogram (mL/kg)
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 1 and 2
milliliters/kilogram (mL/kg)IMC-1121B 10 mg/kg (Cohort 3)
Cycle 140.7 ± 1.22
Cycle 2 (n=0)NA ± NA
PrimaryIMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 3 to 5

Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.

Time frame:
Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour post-dose

No measurements were reported for this outcome.

SecondaryScreen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity)

Data presented are the number of participants with treatment emergent antibody positive.

Time frame:
Baseline to study completion up to 48 weeks
Reported as:
Number · participants
Screen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity)
participantsIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)
Screen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity)000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMC-1121B 6 mg/kg (Cohort 1)—1/3 (33.3%)3/3 (100%)
IMC-1121B 8 mg/kg (Cohort 2)—2/6 (33.3%)6/6 (100%)
IMC-1121B 10 mg/kg (Cohort 3)—2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)
HospitalisationSurgical and medical procedures1/32/61/6
SyncopeNervous system disorders0/30/61/6
Most frequent other events
Showing 10 of 70
Most frequent other events
EventIMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)
Vaginal haemorrhageReproductive system and breast disorders1/10/50/3
HeadacheNervous system disorders1/34/65/6
PyrexiaGeneral disorders1/32/64/6
Abdominal pain upperGastrointestinal disorders2/30/60/6
DiarrhoeaGastrointestinal disorders2/32/61/6
Aspartate aminotransferase increasedInvestigations2/32/62/6
DizzinessNervous system disorders2/31/60/6
AcneSkin and subcutaneous tissue disorders2/31/61/6
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders2/31/60/6
FatigueGeneral disorders1/31/63/6

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)Total
<=18 years0000
Between 18 and 65 years36413
>=65 years0022
Sex: Female, Male
Sex: Female, Male(Participants)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)Total
Female1539
Male2136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)Total
Asian36615
Region of Enrollment
Region of Enrollment(participants)IMC-1121B 6 mg/kg (Cohort 1)IMC-1121B 8 mg/kg (Cohort 2)IMC-1121B 10 mg/kg (Cohort 3)Total
Japan36615
08

Study locations

1 site
  • ImClone Investigational Site
    Tokyo, 104-0045, Japan
09

References and documents

Publications

  • Nokihara H, Yamamoto N, Yamada Y, Honda K, Asahina H, Tamura Y, Hozak RR, Gao L, Suzukawa K, Enatsu S, Tamura T. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2017 Apr 1;47(4):298-305. doi: 10.1093/jjco/hyx008. PubMed 28158463 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2009
First posted
Oct 30, 2009
Start
Sep 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Jun 18, 2014
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01005355
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 30, 2009
Start date
Sep 2009
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Jun 18, 2014
Last update
Jun 18, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion